Evidence map›Paper›PMID 24734120›Full record

ArticleJournal of drug delivery science and technology2013

An inulin and doxorubicin conjugate for improving cancer therapy.

C A Schoener, B Carillo-Conde, H N Hutson, N A Peppas

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug delivery science and technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Microbiota modification in hematology: still at the bench or ready for the bedside?Hematology. American Society of Hematology. Education Program · 2019
    Review
  12. Review
  13. Article
  14. Review
  15. Anticancer effects of the microbiome and its products.Nature reviews. Microbiology · 2017
    Review
  16. Gut microbiota modulation of chemotherapy efficacy and toxicity.Nature reviews. Gastroenterology & hepatology · 2017
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

C A SchoenerDepartment of Chemical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
B Carillo-CondeDepartment of Biomedical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
H N HutsonDepartment of Biomedical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
N A PeppasDepartment of Chemical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA ; Department of Biomedical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA ; College of Pharmacy, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
The University of Texas at Austin · US

Funding

TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CURLEY, STEVEN ALAN · 2009 to 2014
$10.8M
pH Sensitive Complex Hydrogels for Protein Drug ReleaseR01EB000246 · NIBIB · UNIVERSITY OF TEXAS AUSTIN · PI LOWMAN, ANTHONY M, PEPPAS, NICHOLAS A · 2002 to 2014
$3.8M
NCI NIH HHS U54 CA143837NIBIB NIH HHS R01 EB000246
6 · The paper itself

Abstract

Chemotherapy is one of the primary treatment mechanisms for treating cancer. Current chemotherapy is systemically delivered and causes significant side effects; therefore the development of new chemotherapeutic agents or enhancing the effectiveness of current chemotherapeutic could prove vital to patients and cancer care. The purpose of this research was to develop a new conjugate composed of doxorubicin (chemotherapeutic) and inulin (polysaccharide chain) and evaluate its potential as a new therapeutic agent for cancer treatment. The synergistic effect of inulin conjugated to doxorubicin has allowed the same cytotoxic response to be maintained or improved at lower doses as compared to doxorubicin. Supporting results include cytotoxicity profiles, calf thymus DNA binding studies, confocal microscopy, and transport studies.

Indexed as

ConjugateCytotoxicityDoxorubicinDrug resistanceInulin

Identifiers

PMID24734120
PMCPMC3984582
OpenAlexW2162206187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.